In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir

Ledipasvir (LDV; GS-5885), a component of Harvoni (a fixed-dose combination of LDV with sofosbuvir [SOF]), is approved to treat chronic hepatitis C virus (HCV) infection. Here, we report key preclinical antiviral properties of LDV, including in vitro potency, in vitro resistance profile, and activit...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Antimicrob Agents Chemother
Главные авторы: Cheng, Guofeng, Tian, Yang, Doehle, Brian, Peng, Betty, Corsa, Amoreena, Lee, Yu-Jen, Gong, Ruoyu, Yu, Mei, Han, Bin, Xu, Simin, Dvory-Sobol, Hadas, Perron, Michel, Xu, Yili, Mo, Hongmei, Pagratis, Nikos, Link, John O., Delaney, William
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Microbiology 2016
Предметы:
Antiviral Agents
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4775926/
https://ncbi.nlm.nih.gov/pubmed/26824950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02524-15
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы